scientific collaborators

EntreChem has built a network of collaborators and key opinion leaders who actively help the company to add value to our drugs.

For the development of new molecules, EntreChem actively collaborates with a number of national and international research groups in order to characterize the Mechanism of Action and identify biomarkers and sensitive tumors.


  • Academic Researchers

  • Topic

  • Carlo Catapano, Ph.D., M.D., Institute for Oncology Research (Bellinzona, Switzerland)
  • Pina Carbone, Ph.D., Institute for Oncology Research (Bellinzona, Switzerland)
  • Prostate cancer
  • Patrick Grohar, Ph.D., M.D., Children’s Hospital of Philadelphia (Pennsylvania, USA)
  • Ewing sarcoma
  • David Schrump, Ph.D., M.D., NCI (Bethesda, USA)
  • Lung cancer
  • Atanasio Pandiella, Ph.D., CIC (Salamanca, Spain)
  • Triple negative breast cancer and other tumors
  • Alberto Ocaña, Ph.D., M.D., Hospital Clínico San Carlos (Madrid, Spain)
  • Triple negative breast cancer and other tumors
  • Pablo Menéndez, Ph.D., Josep Carreras Leukaemia Research Institute (Barcelona, Spain)
  • Leukaemia
  • Jesús Paramio, Ph.D., CIEMAT (Madrid, Spain)
  • Mario Hermsen, Ph.D., IUOPA (Oviedo, Spain)
  • Head&Neck cancer
  • Segundo González, Ph.D., M.D. University of Oviedo (Spain)
  • Oncoimmunology
  • René Rodríguez, Ph.D., IUOPA (Oviedo, Spain)
  • Sarcoma
  • Jose Luis Fernández-Luna, Ph.D., Hospital Valdecilla (Santander, Spain)
  • Carmen Rodríguez, Ph.D., University of Oviedo (Spain)
  • Serafín Costilla, Ph.D., M.D., HUCA (Oviedo, Spain)
  • Glioblastoma
  • José Portugal, Ph.D., IBMB-CSIC (Barcelona, Spain)
  • Mithralogs DNA-Binding Mechanisms
  • Jurgen Rohr, Ph.D., University of Kentucky (USA)
  • Combinatorial biosynthesis